US Patent 7,722,856 (Drug/Medical): What Is Claimed and Where the Landscape Lands
US Drug Patent 7,722,856 claims a tightly sequenced production-and-delivery method for an inhalable radiopharmaceutical aerosol built from electrolytic loading in a carbon crucible, followed by solvent/salt removal by sublimation, then high-temperature ablation in an inert atmosphere and direct delivery to the patient.
The patent’s claim set is dominated by process mechanics that define (1) how technetium (or other isotopes) is placed in the carbon crucible, (2) how residual solvent and salt impurities are removed, (3) ablation conditions that set aerosol formation, and (4) workflow timing that routes aerosol to patient imaging rather than collecting and reformulating.
What Do Claims 1–21 Actually Cover (Core Claim Architecture)?
Claim 1: Central method claim (process + direct delivery)
Claim 1 recites a method for forming an inhalable isotope compound for patient medical diagnosis with these steps:
- Electrolytic loading
- Carbon crucible is loaded “via electrolysis” with isotope from a solvent that includes the isotope plus other contaminants in solution.
- Sublimation of remaining solvent
- Remaining solvent is sublimated in the crucible after loading.
- Ablation in the crucible
- Isotope is “subsequently ablated” in the carbon crucible, forming an ablation aerosol.
- Direct delivery to patient
- Aerosol is “directly delivering” for immediate use by the patient.
This claim is the anchor because dependent claims refine parameters (flow, current, time, temperatures, inert gas atmosphere), specify isotope type (technetium), and add operational validation steps.
Dependent claims: Parameter lock-in and impurity management
The dependent claims add specific “knobs” that narrow scope around a particular manufacturing window.
Isotope identity
- Claim 2: isotope comprises technetium.
Electrolytic loading parameters
- Claim 3: electrolytic flow transitioning the crucible 0.1 to 0.7 mL/min.
- Claim 4: current through carbon crucible 1 to 10 mA.
- Claim 5: duration of electrolytic loading 10 to 60 minutes.
Solvent composition
- Claim 6: isotope solvent also contains a salt.
- Claim 7: salt includes sodium chloride.
Inert atmosphere details
- Claim 8: sublimation occurs in an argon atmosphere.
- Claim 9: argon purging a chamber for 2 to 10 minutes.
Temperature and dwell windows
- Claim 10: sublimation temperature 1200 to 1800 °C.
- Claim 11: sublimation duration 5 to 20 seconds.
Ablation conditions
- Claim 12: ablation occurs in an argon atmosphere.
- Claim 13: temperature rise time for ablation 0.3 to 0.7 seconds.
- Claim 14: ablation temperature 2740 to 2780 °C.
- Claim 15: ablation duration 2.5 to 3.5 seconds.
Patient-use routing
- Claim 16: ablated isotope aerosol is forwarded directly for medical imaging.
Process monitoring
- Claims 17–18: aerosol periodically captured in water; analysis for operational efficiency includes measurement of:
- free pertechnetate levels
- excess carbon levels
Claims 19–21: Alternative framing of the same workflow (solvent/salt sublimation; electrolytic precipitation + optional sublimation)
These claims restate the method using different emphasis.
- Claim 19: electrolytic loading in a carbon crucible, followed by sublimation that removes “remaining solvent, including dissolved isotope, and salt impurities.”
- Claim 20: electrolytic loading where isotope is “precipitated from solution in said carbon crucible via electrolysis,” then ablated to form ablation aerosol.
- Claim 21: adds that after electrolytic precipitation, any remaining solution and salts are sublimated prior to ablation.
Scope: What Must a Competitor Do to Infringe? (Element-by-Element Exposure)
For method claims, infringement risk tracks whether a manufacturer practices the claimed steps in the claimed order (or equivalent steps that meet the claim limitations).
The “three-stage core” that defines infringement
A process that avoids any one stage may avoid the claim:
- Electrolytic loading into a carbon crucible from isotope-in-solvent (with contaminants).
- Sublimation to remove solvent (and potentially salt impurities).
- Ablation in the crucible to form an inhalable aerosol, then direct patient delivery.
Claim 1 additionally requires suitability for patient medical diagnosis and direct delivery for immediate use.
High-risk design choices
The claim set creates the highest infringement risk when a system matches all of the following:
- Carbon crucible as the substrate for isotope deposition and ablation.
- Electrolysis-based deposition (loading/precipitation) rather than chemical reduction or cartridge-based reconstitution.
- Argon-controlled sublimation and ablation, indicating an engineered thermal environment.
- Ablation temperature and timing in the narrow window:
- 2740–2780 °C
- 2.5–3.5 seconds ablation
- 0.3–0.7 seconds temperature rise
- Solvent includes salts, with examples explicitly pointing to NaCl.
- Operational loop that monitors via capture in water and analysis of free pertechnetate and excess carbon.
Parameter claims: Do they limit infringement?
Dependent claims (3–5, 8–15, 17–18) narrow the scope if used as limitations in a claim combination. Practically, they matter in two ways:
- If a competitor practices only the “broad” version (claim 1 or claim 19–20 phrasing) but not the exact parameters, they may still face risk from the independent or broadly worded claims.
- If a competitor’s process mirrors the specific windows (flow/current/time/temperatures), risk expands toward full dependent-claim alignment.
Claim Coverage Map: Independent vs Narrow-Technical Features
Independents / broadly written method claims
- Claim 1: broadest anchor with the full workflow including direct patient delivery.
- Claim 19: broadly worded variant focusing on sublimation of solvent/isotope and salt impurities after electrolytic loading.
- Claim 20: variant focusing on electrolytic precipitation followed by ablation.
- Claim 21: narrows with “optional but claimed” sublimation step after precipitation prior to ablation.
Most restrictive dependent features
These are the “signature” elements that narrow practice:
- Argon purging duration: 2–10 minutes (claim 9)
- Sublimation conditions: 1200–1800 °C for 5–20 seconds (claims 10–11)
- Ablation conditions: 2740–2780 °C; 0.3–0.7 sec rise; 2.5–3.5 sec duration (claims 13–15)
- Electrolysis control: 0.1–0.7 mL/min transition flow, 1–10 mA, 10–60 minutes (claims 3–5)
- Salt content: includes NaCl example (claims 6–7)
- Quality/efficiency monitoring metrics: free pertechnetate and excess carbon (claims 17–18)
How This Reads Against Common Technetium Aerosol Production Approaches (Competitor Positioning)
Without relying on external assumption about each competitor’s full workflow, the patent’s structure indicates where alternatives tend to diverge:
Likely non-infringing directions
Processes that diverge on at least one of these dimensions reduce overlap:
- Not using electrolysis to load/precipitate technetium (or other isotope) into a carbon crucible
- Not using a sublimation step to remove solvent/salt impurities prior to ablation
- Using a different substrate material than carbon crucible
- Avoiding direct delivery of ablation aerosol for immediate patient use (for example, capturing and reformulating, if that process is materially different in the claim’s “direct delivery” step)
Highest overlap direction
Systems that:
- implement an electrochemical deposition/precipitation,
- include controlled sublimation under argon,
- then perform ultra-hot ablation in argon with a tight thermal profile,
- and route the resulting aerosol immediately into an inhalation pathway.
Patent Landscape: Practical Questions for Freedom-to-Operate
This patent’s claim drafting suggests it is designed to own a whole “module” in a workflow rather than a single component. That creates two landscape implications for R&D and investors:
Landscape implication 1: Risk is process-based, not chemistry-only
Even if an alternative produces technetium in a different chemical form, claim coverage hinges on process steps (electrolysis + sublimation + ablation + direct delivery). A competitor must design around the sequence and the specific physical operations.
Landscape implication 2: Tight thermal windows can act as “fences”
The explicit temperature, rise time, and ablation duration are likely intended to distinguish over prior art systems and define operational fingerprints. If a competitor uses different ablation conditions outside those windows, they may reduce dependent-claim alignment. But claim 1 can still be implicated if the independent limitations are met (unless the differences are material to those independent features).
Decision-Grade Infringement Sensitivity (What to Look for in Product Specs)
Use these items as “evidence targets” when assessing a specific system:
| Evidence target in the accused process |
Why it matters to 7,722,856 |
| Carbon crucible used for deposition and ablation |
Central limitation in claim 1 and variants (claims 19–20) |
| Electrolytic loading/precipitation from an isotope solvent |
Defines the method’s deposition mechanism |
| Sublimation step separating “remaining solvent” |
Explicitly required before ablation |
| Argon atmosphere for sublimation and ablation |
Dependent claims specify argon; also supports engineered system match |
| Ablation at ~2740–2780 °C for 2.5–3.5 sec with 0.3–0.7 sec rise |
Dependent claim fence (claims 13–15) |
| Direct routing of ablation aerosol to the patient |
Claim 1 and claim 16 |
| Monitoring via water capture with free pertechnetate and excess carbon |
Operational efficiency analysis claimed in claims 17–18 |
| Electrolytic flow/current/loading time |
Dependent constraints (claims 3–5) |
| Salt presence in solvent (NaCl example) |
Dependent constraints (claims 6–7) |
Key Takeaways
- US 7,722,856 claims a specific radiology workflow: electrolytic deposition into a carbon crucible, sublimation removal of solvent (and salt impurities), argon-based ablation to form an inhalable aerosol, and direct delivery to the patient.
- The broadest hook is Claim 1, which ties together the entire sequence and immediate patient delivery. Claims 19–21 reinforce variations centered on sublimation of dissolved isotope/salt and electrolytic precipitation.
- The most defensible narrowing features are the tight process parameters: electrolytic current/flow/time, sublimation temperature and duration, and ablation temperature/rise time/duration, plus argon purging and salt-containing solvents.
- The landscape risk for competitors is highest when their systems match the same sequence and the same operational thermal envelope, especially around ablation and sublimation.
FAQs
1) Is this patent focused on isotope chemistry or device engineering?
It is focused on a process combining deposition, purification by sublimation, ablation, and direct patient delivery.
2) What is the “signature” technical step for infringement risk?
The combination of electrolytic loading into a carbon crucible, then sublimation, then high-temperature ablation in argon producing an inhalable aerosol for immediate patient use (Claim 1).
3) If a system uses technetium but not argon, does it avoid the patent?
Argon is explicitly required in dependent claims for sublimation and ablation (claims 8, 12). Avoiding argon may reduce alignment with those dependents, but Claim 1 still requires the broader sequence; infringement depends on how the system maps to the independent limitations.
4) Are the thermal numbers (2740–2780 °C, etc.) critical?
They appear in dependent claims (13–15) and act as strong distinguishing limitations. Systems matching those windows face higher risk of dependent-claim capture.
5) Does the patent claim monitoring or quality control steps?
Yes. Claims 17–18 recite periodic capture of the aerosol in water and analysis of free pertechnetate levels and excess carbon levels for operational efficiency.
References (APA)
[1] United States Patent No. 7,722,856, “Method for forming an inhalable isotope compound for patient medical diagnosis,” claims 1–21.
